Temporal Patterns of Antithrombotic Therapy and Clinical Outcomes After Atrial Fibrillation‐Related Stroke
Journal of the American Heart Association · 2026
DOI: 10.1161/jaha.125.045364 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Keon-Joo Lee und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology Korea University Guro Hospital Seoul Korea. Hauptthemen laut MEDLINE: Anticoagulants, Atrial Fibrillation, Fibrinolytic Agents, Ischemic Stroke. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
This study aimed to describe the temporal evolution of antithrombotic treatment strategies and associated clinical outcomes after atrial fibrillation‐related acute ischemic stroke.
Methods
This multicenter prospective cohort study enrolled patients with acute ischemic stroke and atrial fibrillation from 16 tertiary stroke centers across South Korea between February 2018 and January 2021, with follow‐up completed by January 2022. The primary outcome was a composite of recurrent stroke, myocardial infarction, and all‐cause death. Secondary outcomes included individual components of the primary outcome and major bleeding events.
Results
The median follow‐up duration was 1.92 years. Among 2965 patients (mean±SD age, 75.3 [10.2] years; 54.1% male), antithrombotic strategies varied widely in the acute phase. Within 48 hours of admission, 50.9% received antiplatelet‐only therapy (29.4% single, 21.5% dual), 23.2% received non–vitamin K antagonist oral anticoagulant monotherapy, and 10.4% received a combination of antiplatelets and anticoagulants. By discharge, non–vitamin K antagonist oral anticoagulant monotherapy had become the predominant treatment strategy (65.7%), and this pattern persisted throughout follow‐up. The incidence of the primary end point was highest in the first 2 weeks (32.70 [95% CI, 29.64–36.06] per 100 person‐months) and declined thereafter. Across all time periods, patients receiving non–vitamin K antagonist oral anticoagulant monotherapy consistently had lower incidence rates (3‐month rate, 4.95 [95% CI, 4.37–5.61] per 100 person‐months) than those receiving antiplatelet‐only therapy (11.98 [95% CI, 9.57–15.01]) or no antithrombotic therapy (18.44 [95% CI, 14.26–23.86]).
Conclusions
In this prospective cohort of patients with atrial fibrillation‐related stroke, early antithrombotic treatment strategies were heterogeneous but evolved primarily toward use of non–vitamin K antagonist oral anticoagulant monotherapy. Treatment selection was associated with marked differences in outcomes, particularly during the early high‐risk period.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology Korea University Guro Hospital Seoul Korea.
- Department of Biostatistics Korea University College of Medicine Seoul Korea.
- Department of Neurology Seoul National University Bundang Hospital Seongnam Korea.
- Department of Neurology Chonnam National University Hospital Gwangju Korea.
- Department of Neurology Chungbuk National University & Hospital Cheongju Korea.
- Department of Neurology Dong-A University Hospital Busan Korea.
ORCID-Profile: Keon-Joo Lee, Han-Gil Jeong, Beom Joon Kim, Moon-Ku Han, Joon-Tae Kim, Kang-Ho Choi, Dong-Ick Shin, Jae-Kwan Cha, Dae-Hyun Kim, Dong-Eog Kim, Jong-Moo Park, Kyusik Kang, Soo Joo Lee, Jae Guk Kim, Mi-Sun Oh, Kyung-Ho Yu, Byung-Chul Lee, Keun-Sik Hong, Yong-Jin Cho, Jay Chol Choi, Tai Hwan Park, Kyungbok Lee, Jee-Hyun Kwon, Wook-Joo Kim, Jun Lee, Ji Sung Lee, Da Young Hong, Juneyoung Lee, Philip B Gorelick, Hee-Joon Bae
Zitieren
APA
Lee, K. J., Oh, H., Jeong, H. G., Kim, B. J., Han, M. K., Kim, J. T., Choi, K. H., Shin, D. I., Cha, J. K., Kim, D. H., Kim, D. E., Park, J. M., Kang, K., Lee, S. J., Kim, J. G., Oh, M. S., Yu, K. H., Lee, B. C., Hong, K. S., …, & CRCS‐K (Clinical Research Collaboration for Stroke in Korea) investigators (2026). Temporal Patterns of Antithrombotic Therapy and Clinical Outcomes After Atrial Fibrillation‐Related Stroke. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.045364
Vancouver
Lee KJ, Oh H, Jeong HG, Kim BJ, Han MK, Kim JT, et al. Temporal Patterns of Antithrombotic Therapy and Clinical Outcomes After Atrial Fibrillation‐Related Stroke. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.045364
BibTeX
@article{Lee2026,
author = {Lee, Keon-Joo and Oh, Hoonji and Jeong, Han-Gil and Kim, Beom Joon and Han, Moon-Ku and Kim, Joon-Tae and Choi, Kang-Ho and Shin, Dong-Ick and Cha, Jae-Kwan and Kim, Dae-Hyun and Kim, Dong-Eog and Park, Jong-Moo and Kang, Kyusik and Lee, Soo Joo and Kim, Jae Guk and Oh, Mi-Sun and Yu, Kyung-Ho and Lee, Byung-Chul and Hong, Keun-Sik and Cho, Yong-Jin and Choi, Jay Chol and Park, Tai Hwan and Lee, Kyungbok and Kwon, Jee-Hyun and Kim, Wook-Joo and Lee, Jun and Lee, Ji Sung and Hong, Da Young and Lee, Juneyoung and Gorelick, Philip B and Bae, Hee-Joon and CRCS‐K (Clinical Research Collaboration for Stroke in Korea) investigators, CRCS‐K (Clinical Research Collaboration for Stroke in Korea) investigators},
title = {Temporal Patterns of Antithrombotic Therapy and Clinical Outcomes After Atrial Fibrillation‐Related Stroke},
journal = {Journal of the American Heart Association},
year = {2026},
doi = {10.1161/jaha.125.045364}
}
EUVIMED